Last reviewed · How we verify

Lovastatin Tablet — Competitive Intelligence Brief

Lovastatin Tablet (Lovastatin Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin (HMG-CoA reductase inhibitor). Area: Cardiovascular.

marketed Statin (HMG-CoA reductase inhibitor) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lovastatin Tablet (Lovastatin Tablet) — National Taiwan University Hospital. Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lovastatin Tablet TARGET Lovastatin Tablet National Taiwan University Hospital marketed Statin (HMG-CoA reductase inhibitor) HMG-CoA reductase
Crestor rosuvastatin AstraZeneca marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 2003-01-01
Lipitor atorvastatin Pfizer Inc. marketed HMG-CoA reductase inhibitor (statin) HMG-CoA reductase 1996-12-17
FLUVASTATIN SODIUM FLUVASTATIN SODIUM marketed HMG-CoA reductase 1993-01-01
Lescol FLUVASTATIN Novartis marketed HMG-CoA Reductase Inhibitor HMG-CoA reductase 1993-01-01
Ezetimibe and Simvastatin Ezetimibe and Simvastatin University of Texas Southwestern Medical Center marketed Combination lipid-lowering agent (ezetimibe + statin) NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Atorvastatin-omeprazole Atorvastatin-omeprazole Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec marketed Fixed-dose combination (statin + proton pump inhibitor) HMG-CoA reductase (atorvastatin); H+/K+-ATPase (omeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Statin (HMG-CoA reductase inhibitor) class)

  1. Organon and Co · 2 drugs in this class
  2. AstraZeneca · 1 drug in this class
  3. Mitsukoshi Health and Welfare Foundation · 1 drug in this class
  4. National Taiwan University Hospital · 1 drug in this class
  5. Shenyang Northern Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lovastatin Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/lovastatin-tablet. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: